Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen, PDL BioPharma encouraged my MS drug data
The study, known as the Choice trial, is evaluating the efficacy and safety of daclizumab or placebo added to interferon beta therapy in 230 patients with active multiple
The study, known as the Choice trial, is evaluating the efficacy and safety of daclizumab or placebo added to interferon beta therapy in 230 patients with active multiple
The clinical trial utilized a two stage design to ensure there would be an adequate response rate to justify complete enrollment. Tumor response was evaluated at baseline and
Sofgen will be responsible for development and manufacturing of the product. Akorn will be responsible for the regulatory submission, marketing and distribution in the US and Puerto Rico.
Ralph Makar, the newly appointed president and CEO of Bioject, said: “We are pleased to enter into this new agreement with Merck Serono, which is the continuation of
This agreement provides Sirtris with exclusive rights to intellectual property covered under the patent ‘cholesterol-regulating complex of SIRT1 and LXR and methods of use.’ Karl Normington, Sirtris’ senior
Under the terms of the offering, CombinatoRx will sell 5.6 million shares of its common stock at a price of $6.25 per share, which represents a 6.5% discount
This study will enroll approximately 56 evaluable patients. The primary efficacy objective is the response rate (confirmed complete response or confirmed complete response without platelet recovery) achieved over
The payment is in the form of equity securities in iCo Therapeutics. The licensed drug designed and discovered by Isis, iCo-007, is a second-generation antisense drug that inhibits
Under the terms of the agreement, QLT will acquire all of the outstanding shares of ForSight Newco II for $42 million on closing along with future milestone payments
The randomized, double-blind, placebo controlled, dose-escalation study achieved statistical significance in its primary endpoint of mean change in FEV1 (forced expiratory volume in 1 second) from baseline at